EMERYVILLE, Calif., June 27, 2024 /PRNewswire/ — Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the first participant has been dosed in a Phase 1/2 clinical trial evaluating…
[ad_2]
Source link
